Intentar ORO - Gratis
Markets See Red as Indo-Pak Tensions Continue to Rise
Mint Chennai
|May 10, 2025
The set up indicates continuation of the downside pressure, unless tensions abate
Benchmark indices closed in the red for the second straight session on Friday amid fears of India and Pakistan escalating tensions. While both Nifty and Sensex recovered from their intraday lows, anticipation of tensions over the weekend led foreign portfolio investors (FPIs) to press the sell button in both the cash and derivatives segment.
The setup by the end of the day indicates continuation of the downside pressure, unless tensions abate. Selling in heavyweights such as ICICI Bank, HDFC Bank and Reliance Industries dragged both Nifty and Sensex down by 1.1% each. Nifty closed down by 266 points at 24,008, slightly below its 200-day moving average of 24,044.25, a bearish sign. The Sensex, which settled 880 points lower at 79,454.47, managed to close slightly above its 200 DMA of 79,114, per Bloomberg data.
FPIs' changed stance in cash markets on Friday—they sold shares worth a provisional ₹3,798.71 crore—came after sixteen straight sessions of net buying ₹16,473 crore. FPIs also sold index and stock futures worth a net ₹4,346 crore amid escalating tensions, BSE and National Stock Exchange (NSE) data showed. The sale of index futures on Friday once again made them cumulatively net short after two days.
Esta historia es de la edición May 10, 2025 de Mint Chennai.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Mint Chennai
Mint Chennai
Lenskart wants artificial intelligence to test your eyes
It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery
3 mins
January 13, 2026
Mint Chennai
More companies to take a hit as labour codes debut
Reworked gratuity and leave encashments spell additional expenses for India Inc
2 mins
January 13, 2026
Mint Chennai
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Chennai
Trump’s investigation of Powell is also a warning to the next Fed chair
The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.
3 mins
January 13, 2026
Mint Chennai
States flag Almont-Kid syrup as tests find contaminants
Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol
1 mins
January 13, 2026
Mint Chennai
India at 100: Our choices today will define the next two decades
India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path
4 mins
January 13, 2026
Mint Chennai
Now, inheritance works without probate—but why it still matters
Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases
6 mins
January 13, 2026
Mint Chennai
Why VCs have a new deep-tech playbook
where fundraising starts to drag,\" said Chand.
1 min
January 13, 2026
Mint Chennai
TCS, HCLTech deliver Q3 revenue surprise
clearer.
2 mins
January 13, 2026
Mint Chennai
US productivity is rising and it risks warping monetary policy
America's neutral rate ought to be going up but will the Fed listen?
3 mins
January 13, 2026
Listen
Translate
Change font size
